Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Boonen, S; Reginster, JY; Kaufman, JM; Lippuner, K; Zanchetta, J; Langdahl, B; Rizzoli, R; Lipschitz, S; Dimai, HP; Witvrouw, R; Eriksen, E; Brixen, K; Russo, L; Claessens, F; Papanastasiou, P; Antunez, O; Su, GQ; Bucci-Rechtweg, C; Hruska, J; Incera, E; Vanderschueren, D; Orwoll, E; .
Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis.
N ENGL J MED. 2012; 367(18): 1714-1723.
Doi: 10.1056/NEJMoa1204061
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Dimai Hans Peter
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Background Fractures in men are a major health issue, and data on the antifracture efficacy of therapies for osteoporosis in men are limited. We studied the effect of zoledronic acid on fracture risk among men with osteoporosis. Methods In this multicenter, double-blind, placebo-controlled trial, we randomly assigned 1199 men with primary or hypogonadism-associated osteoporosis who were 50 to 85 years of age to receive an intravenous infusion of zoledronic acid (5 mg) or placebo at baseline and at 12 months. Participants received daily calcium and vitamin D supplementation. The primary end point was the proportion of participants with one or more new morphometric vertebral fractures over a period of 24 months. Results The rate of any new morphometric vertebral fracture was 1.6% in the zoledronic acid group and 4.9% in the placebo group over the 24-month period, representing a 67% risk reduction with zoledronic acid (relative risk, 0.33; 95% confidence interval, 0.16 to 0.70; P = 0.002). As compared with men who received placebo, men who received zoledronic acid had fewer moderate-to-severe vertebral fractures (P = 0.03) and less height loss (P = 0.002). Fewer participants who received zoledronic acid had clinical vertebral or nonvertebral fractures, although this difference did not reach significance because of the small number of fractures. Bone mineral density was higher and bone-turnover markers were lower in the men who received zoledronic acid (PANDlt;0.05 for both comparisons). Results were similar in men with low serum levels of total testosterone. The zoledronic acid and placebo groups did not differ significantly with respect to the incidence of death (2.6% and 2.9%, respectively) or serious adverse events (25.3% and 25.2%). Conclusions Zoledronic acid treatment was associated with a significantly reduced risk of vertebral fracture among men with osteoporosis. (Funded by Novartis Pharma; ClinicalTrials.gov number, NCT00439647.)
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Aged, 80 and over -
- Analysis of Variance -
- Bone Density - drug effects
- Bone Density Conservation Agents - adverse effects Bone Density Conservation Agents - pharmacology Bone Density Conservation Agents - therapeutic use
- Diphosphonates - adverse effects Diphosphonates - pharmacology Diphosphonates - therapeutic use
- Double-Blind Method -
- Humans -
- Hypogonadism - complications
- Imidazoles - adverse effects Imidazoles - pharmacology Imidazoles - therapeutic use
- Logistic Models -
- Male -
- Middle Aged -
- Osteoporosis - drug therapy Osteoporosis - etiology
- Risk -
- Spinal Fractures - epidemiology Spinal Fractures - prevention and control
- Testosterone - blood